News - OBI Pharma 台灣浩鼎

2023.Dec.06

未分類

Corporate

OBI Pharma proprietary ADC technology platform “plug and play”

2023.Nov.23

未分類

Corporate

Award & Certification

OBI Achieves ISO/IEC 27001 International Information Security Certification

2023.Nov.01

未分類

Sustainability

OBI VOLUNTEERS ON A MISSION!

2023.Jun.02

Corporate

OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. appointed as Chief Executive Officer

2023.Apr.20

Corporate

Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

2023.Apr.10

Corporate

OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

2022.Jul.05

Corporate

OBI Pharma Announces Discontinuation of the Phase 1/2 Study of its Antibody- OBI 888 to focus on other priority Cancer programs

2022.Jun.06

Corporate

Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, and OBI-3424

2022.May.17

Corporate

OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth

2022.Apr.08

Corporate

Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

Announcements

Latest announcements

Events

Latest events